Royalty pharma plc RPRX 深 沪
已收盘 10-09 16:00:00 美东时间
56.93
+0.720
+1.28%
华盛通- 最 高57.08
- 今 开56.03
- 成交量 288.20万股
- 最 低 55.72
- 昨 收 56.21
- 总市值 327.35亿
- 52周最高 64.38
- 市盈率 静 31.96
- 换手率 0.50%
- 52周最低 34.99
- 委 比 -80.80%
- 总股本 5.75亿
- 历史最高 64.38
- 量 比 0.95
- 振 幅 2.42%
- 历史最低 22.465
- 每 手 1
- 风险率 8.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.
10-07 22:56
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization of $25.92 billion. Buying $100 In RPRX: If an investor had bought $100 of RPRX stock 10...
09-30 04:30
美股夜盘 | 阿里巴巴上升3.20%，Forgent Power Solutions上升2.94%
阿里巴巴上升3.20%；Forgent Power Solutions上升2.94%；Lumentum上升2.81%
09-18 15:01
美股夜盘 | Pembina Pipeline走高4.95%，Moog-A上升3.52%
Pembina Pipeline走高4.95%；Moog-A上升3.52%；Strategy上升2.42%
09-18 13:01
Royalty Pharma to present at upcoming investor conferences
Royalty Pharma plc will participate in two investor conferences in September 2026: the Morgan Stanley Global Healthcare Conference on September 14 and the BofA Global Research Global Healthcare Conference on September 23. The webcasts will be available on Royalty Pharma’s website and archived for at least 30 days. Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties, collaborating with innovators across the industry...
09-09 20:05
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM...
09-08 20:01
